TargetMol

Lawsone methyl ether

Product Code:
 
TAR-T3008
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3008-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3008-50mg50mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Bioactivity:
MNQ induced apoptosis of A549 cells independent of cell cycle arrest, and is mediated by the JNK and p38 MAPK signaling pathways. Further analysis demonstrated that these signaling pathways were stimulated by oxidative DNA damage caused by increased ROS generation in MNQ-treated A549 cells.
CAS:
2348-82-5
Formula:
C11H8O3
Molecular Weight:
188.182
Pathway:
Apoptosis; Microbiology/Virology
Purity:
0.9941
SMILES:
COC1=CC(=O)c2ccccc2C1=O
Target:
Apoptosis; Antibacterial; Antifungal

References

1. Ong J Y H , Yong P V C , Lim Y M , et al. 2-Methoxy-1,4-naphthoquinone (MNQ) induces apoptosis of A549 lung adenocarcinoma cells via oxidation-triggered JNK and p38 MAPK signaling pathways[J]. Life Sciences, 2015, 135:158-164. 2. Parat V, Onteniente B, Maruotti J. A high?throughput screening platform for pigment regulating agents using pluripotent stem cell?derived melanocytes[J]. Experimental Dermatology. 2020 3. Parat V, Onteniente B, Maruotti J. A high-throughput screening platform for pigment regulating agents using pluripotent stem cell derived melanocytes[J]. Experimental Dermatology. 2020.